Antihypertensive effectiveness of aliskiren for the 'real-world' management of hypertension: Multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study)

G. A. Verpooten, A. Aerts, N. Coen, S. Vancayzeele, C. Hermans, J. Bowles, K. MacDonald, I. Abraham, Christopher Lee

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aims: The 'DRIVER' study was designed to investigate the 'real-world' effectiveness of aliskiren-based treatment of hypertension. This article reports the 180-day blood pressure (BP) outcomes, and the multilevel (physician- and patient-level) determinants thereof. Methods and results: DRIVER was a prospective, observational, open-label, multi-centre, pharmaco-epidemiologic study of hypertensive patients treated with aliskiren in whom prior treatment failed or was not tolerated. 2070 patients (enrolled by 426 physicians) were enrolled; 1695 patients (81.9%) completed the 180-day aliskiren treatment period. Mean patient age was 64.2 ± 12.1 years; 53.7% were men, 25.3% diabetic and 40.7% had a high or very high cardiovascular (CV) risk. At 180 days, the mean ± SD reductions in systolic and diastolic BP were -22.9 ± 16.7 mmHg and -10.5 ± 10.9 mmHg respectively (both p

Original languageEnglish (US)
Pages (from-to)54-63
Number of pages10
JournalInternational Journal of Clinical Practice
Volume65
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Antihypertensive Agents
Blood Pressure
Hypertension
Physicians
Epidemiologic Studies
Therapeutics
aliskiren

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Antihypertensive effectiveness of aliskiren for the 'real-world' management of hypertension : Multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study). / Verpooten, G. A.; Aerts, A.; Coen, N.; Vancayzeele, S.; Hermans, C.; Bowles, J.; MacDonald, K.; Abraham, I.; Lee, Christopher.

In: International Journal of Clinical Practice, Vol. 65, No. 1, 01.2011, p. 54-63.

Research output: Contribution to journalArticle

Verpooten, G. A. ; Aerts, A. ; Coen, N. ; Vancayzeele, S. ; Hermans, C. ; Bowles, J. ; MacDonald, K. ; Abraham, I. ; Lee, Christopher. / Antihypertensive effectiveness of aliskiren for the 'real-world' management of hypertension : Multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study). In: International Journal of Clinical Practice. 2011 ; Vol. 65, No. 1. pp. 54-63.
@article{0ccd63d845944e2ca0d153ec4a8dae81,
title = "Antihypertensive effectiveness of aliskiren for the 'real-world' management of hypertension: Multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study)",
abstract = "Aims: The 'DRIVER' study was designed to investigate the 'real-world' effectiveness of aliskiren-based treatment of hypertension. This article reports the 180-day blood pressure (BP) outcomes, and the multilevel (physician- and patient-level) determinants thereof. Methods and results: DRIVER was a prospective, observational, open-label, multi-centre, pharmaco-epidemiologic study of hypertensive patients treated with aliskiren in whom prior treatment failed or was not tolerated. 2070 patients (enrolled by 426 physicians) were enrolled; 1695 patients (81.9{\%}) completed the 180-day aliskiren treatment period. Mean patient age was 64.2 ± 12.1 years; 53.7{\%} were men, 25.3{\%} diabetic and 40.7{\%} had a high or very high cardiovascular (CV) risk. At 180 days, the mean ± SD reductions in systolic and diastolic BP were -22.9 ± 16.7 mmHg and -10.5 ± 10.9 mmHg respectively (both p",
author = "Verpooten, {G. A.} and A. Aerts and N. Coen and S. Vancayzeele and C. Hermans and J. Bowles and K. MacDonald and I. Abraham and Christopher Lee",
year = "2011",
month = "1",
doi = "10.1111/j.1742-1241.2010.02562.x",
language = "English (US)",
volume = "65",
pages = "54--63",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Antihypertensive effectiveness of aliskiren for the 'real-world' management of hypertension

T2 - Multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study)

AU - Verpooten, G. A.

AU - Aerts, A.

AU - Coen, N.

AU - Vancayzeele, S.

AU - Hermans, C.

AU - Bowles, J.

AU - MacDonald, K.

AU - Abraham, I.

AU - Lee, Christopher

PY - 2011/1

Y1 - 2011/1

N2 - Aims: The 'DRIVER' study was designed to investigate the 'real-world' effectiveness of aliskiren-based treatment of hypertension. This article reports the 180-day blood pressure (BP) outcomes, and the multilevel (physician- and patient-level) determinants thereof. Methods and results: DRIVER was a prospective, observational, open-label, multi-centre, pharmaco-epidemiologic study of hypertensive patients treated with aliskiren in whom prior treatment failed or was not tolerated. 2070 patients (enrolled by 426 physicians) were enrolled; 1695 patients (81.9%) completed the 180-day aliskiren treatment period. Mean patient age was 64.2 ± 12.1 years; 53.7% were men, 25.3% diabetic and 40.7% had a high or very high cardiovascular (CV) risk. At 180 days, the mean ± SD reductions in systolic and diastolic BP were -22.9 ± 16.7 mmHg and -10.5 ± 10.9 mmHg respectively (both p

AB - Aims: The 'DRIVER' study was designed to investigate the 'real-world' effectiveness of aliskiren-based treatment of hypertension. This article reports the 180-day blood pressure (BP) outcomes, and the multilevel (physician- and patient-level) determinants thereof. Methods and results: DRIVER was a prospective, observational, open-label, multi-centre, pharmaco-epidemiologic study of hypertensive patients treated with aliskiren in whom prior treatment failed or was not tolerated. 2070 patients (enrolled by 426 physicians) were enrolled; 1695 patients (81.9%) completed the 180-day aliskiren treatment period. Mean patient age was 64.2 ± 12.1 years; 53.7% were men, 25.3% diabetic and 40.7% had a high or very high cardiovascular (CV) risk. At 180 days, the mean ± SD reductions in systolic and diastolic BP were -22.9 ± 16.7 mmHg and -10.5 ± 10.9 mmHg respectively (both p

UR - http://www.scopus.com/inward/record.url?scp=78650459102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650459102&partnerID=8YFLogxK

U2 - 10.1111/j.1742-1241.2010.02562.x

DO - 10.1111/j.1742-1241.2010.02562.x

M3 - Article

C2 - 21155943

AN - SCOPUS:78650459102

VL - 65

SP - 54

EP - 63

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 1

ER -